Methods for diagnosing and treating cancer

Patent metadata

Field	Value
Publication number	US-11261498-B2
Application number	US-201916591253-A
Country	US
Kind code	B2
Filing date	Oct 2, 2019
Priority date	Aug 31, 2011
Publication date	Mar 1, 2022
Grant date	Mar 1, 2022

Abstract

The present invention provides methods of treating cancer based on the methylation status of the ERBB2 gene. One aspect of the invention provides a method of administering an EGFR inhibitor therapy based on the methylation status of the ERBB2 gene.

First claim

What is claimed is:

1. A method of treating a cancer patient with an EGFR inhibitor comprising the following steps:
a) detecting the methylation status of the ERBB2 gene from a sample from the patient's cancer;
b) selecting the cancer patient for the treatment if the methylation status of the ERBB2 gene is detected to be hypomethylation; and
c) administering an effective amount of the EGFR inhibitor to the cancer patient, wherein the cancer is lung cancer.

2. The method of claim 1 , wherein the methylation status is detected in a part of the ERBB2 gene.

3. The method of claim 2 , wherein the part of the ERBB2 gene is an enhancer.

4. The method of claim 2 , wherein the part of the ERBB2 gene is an enhancer and a promoter.

5. The method of claim 2 , wherein the part of the ERBB2 gene comprises a 6 CpG repeat region.

6. The method of claim 5 , wherein the part of the ERBB2 gene further comprises the nucleic acid sequence of SEQ ID NO: 2.

7. The method of claim 2 , wherein the part of the ERBB2 gene comprises the nucleic acid sequence of SEQ ID NO:1.

8. The method of claim 1 , where hypomethylation is indicated by less than about 20% methylation of the ERBB2 gene.

9. The method of claim 1 , wherein the EGFR inhibitor is erlotinib, cetuximab or panitumumab.

10. The method of claim 9 , wherein the EGFR inhibitor is erlotinib.

11. The method of claim 1 , wherein the lung cancer is NSCLC.

12. The method of claim 1 , wherein the methylation status is detected by pyrosequencing.

Assignees

• Genentech Inc

Inventors

• Januario Thomas E
• Shames David

Classifications

• C12Q2600/106

  Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title

• A61K31/517 Primary

  ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine · CPC title

• C12Q2600/156

  Polymorphic or mutational markers · CPC title

• C12Q2600/154

  Methylation markers · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title